R&D News | pharmaphorum

News

Brukinsa data raises chemo-free hope for mantle cell lymphom...

Patients with newly diagnosed mantle cell lymphoma could avoid chemotherapy with a regimen based on BeOne's Brukinsa, according to the MANGROVE trial.

News

Sanofi eyes extending Nexviazyme into infantile Pompe

Armed with new phase 3 data, Sanofi will try to expand the US label of its Pompe disease drug Nexviazyme to include the severe infantile-onset form.

News

Ipsen charts $1.75bn course for Kartos acquisition

Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.

News

Moderna shows in vivo CAR-T hand in R&D update

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class to its R&D capabilities.

News

Merck buys life sciences firm Bio-Techne in $11.3bn deal

Merck KGaA is poised to increase the size of its life sciences business with an $11.3 billion deal to acquire rival Bio-techne.

News

Hub-and-spoke firm Osanni raises $190m, and other financings

Our latest roundup of venture capital financings in the biotech sector includes rounds for Osanni Bio, Bionyra, Serapha, Nura Bio, and Oblenio.

Brukinsa data raises chemo-free hope for mantle cell lymphom...

Sanofi eyes extending Nexviazyme into infantile Pompe

Ipsen charts $1.75bn course for Kartos acquisition

Moderna shows in vivo CAR-T hand in R&D update

Merck buys life sciences firm Bio-Techne in $11.3bn deal

Hub-and-spoke firm Osanni raises $190m, and other financings

ASCO 2026: All about DNA damage response, with Luke Piggot

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks